GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma AS (BSP:A1SN34) » Definitions » Debt-to-Equity

Ascendis Pharma AS (BSP:A1SN34) Debt-to-Equity : -4.46 (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Ascendis Pharma AS Debt-to-Equity?

Ascendis Pharma AS's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was R$3,050 Mil. Ascendis Pharma AS's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was R$2,224 Mil. Ascendis Pharma AS's Total Stockholders Equity for the quarter that ended in Mar. 2025 was R$-1,182 Mil. Ascendis Pharma AS's debt to equity for the quarter that ended in Mar. 2025 was -4.46.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Ascendis Pharma AS's Debt-to-Equity or its related term are showing as below:

BSP:A1SN34' s Debt-to-Equity Range Over the Past 10 Years
Min: -9.07   Med: 0.07   Max: 7.8
Current: -4.46

During the past 13 years, the highest Debt-to-Equity Ratio of Ascendis Pharma AS was 7.80. The lowest was -9.07. And the median was 0.07.

BSP:A1SN34's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs BSP:A1SN34: -4.46

Ascendis Pharma AS Debt-to-Equity Historical Data

The historical data trend for Ascendis Pharma AS's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascendis Pharma AS Debt-to-Equity Chart

Ascendis Pharma AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 0.12 1.93 -4.42 -8.10

Ascendis Pharma AS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.81 -2.10 -8.10 -8.10 -4.46

Competitive Comparison of Ascendis Pharma AS's Debt-to-Equity

For the Biotechnology subindustry, Ascendis Pharma AS's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma AS's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma AS's Debt-to-Equity falls into.


;
;

Ascendis Pharma AS Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Ascendis Pharma AS's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Ascendis Pharma AS's Debt to Equity Ratio for the quarter that ended in Mar. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ascendis Pharma AS  (BSP:A1SN34) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Ascendis Pharma AS Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Ascendis Pharma AS's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascendis Pharma AS Business Description

Traded in Other Exchanges
Address
Tuborg Boulevard 12, Hellerup, DNK, DK-2900
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.

Ascendis Pharma AS Headlines

No Headlines